Thus, more and younger women with excellent survival We followed 49 women who underwent a minimum of 2 years prognoses will experience early menopause after treatment estrogen replacement therapy (ERT) after diagnosis and treatment for early-stage breast cancer. These women face several defor localized breast cancer. Forty-three women were treated with cades of estrogen deficiency because current concerns reoral ERT. In this group, the median age at the time of cancer garding the safety of ERT have caused physicians to limit diagnosis was 46 years (range 26 to 66 years), and ERT was begun the use of this treatment.
Thus, more and younger women with excellent survival We followed 49 women who underwent a minimum of 2 years prognoses will experience early menopause after treatment estrogen replacement therapy (ERT) after diagnosis and treatment for early-stage breast cancer. These women face several defor localized breast cancer. Forty-three women were treated with cades of estrogen deficiency because current concerns reoral ERT. In this group, the median age at the time of cancer garding the safety of ERT have caused physicians to limit diagnosis was 46 years (range 26 to 66 years), and ERT was begun the use of this treatment.
a median of 84 months after diagnosis (range 0 to 286 months).
Whether and for which subgroups of breast cancer patients
The patients were followed for a median of 144 months after ERT may be used safely to correct climacteric symptoms cancer diagnosis (range 46 to 324 months), and the median duraand prevent cardiovascular and skeletal morbidities cannot prospective trials. While our own prospective study is ongoIn this group, the median age at time of cancer diagnosis was 46 years (range 38 to 57 years), and ERT was begun a median of 49 ing [15] and plans for related trials are being prepared by months after diagnosis (range 24 to 61 months). The patients were several investigators, results will not be available for a numfollowed for a median of 95 months after cancer diagnosis (range ber of years. In the meantime, there is mounting pressure 72 to 154 months), and the median duration of ERT was 47 months to obtain some information regarding ERT in this growing (range 27 to 80 months). One patient experienced disease recur-population of postmenopausal women. To address this need, rence; she had received surgery for a stage I, estrogen receptor a number of retrospective analyses, including the present (ER)-positive lesion. The patient began ERT 30 months after can-report, are being published to provide some information cer diagnosis and developed a recurrent ER-negative tumor 56 about the potential safety of ERT [16] [17] [18] [19] . history of breast cancer. However, up to 10% of prior patients receive ERT for relief of menopausal health problems [12, 19] . The patients in the present report were followed at INTRODUCTION the University of Texas M. D. Anderson Cancer Center after treatment for breast cancer and have either: (a) received ERT Estrogen replacement therapy (ERT) after a diagnosis of breast cancer is a controversial topic both within the medical through their community physicians and requested surveillance at our institution or (b) joined our prospective study community and among women with the disease. ERT has generally been omitted in this setting, but the validity of and been assigned to the ERT arm. All women included in the study had received ERT for a minimum of 2 years. current practices is increasingly being questioned [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . With screening programs, breast cancer is being diagnosed Treatment was administered orally or as a vaginal cream application. Most women received conjugated estrogen only; at an earlier stage and with improved therapy, survival durations are increasing. Adjuvant chemotherapy is being in-the dose was quite variable due to the unselected, retrospective character of the population. creasingly incorporated into the treatment program for localized disease, but it can accelerate the arrival of menopause.
At the time of breast cancer diagnosis, 18 women were women, by chemotherapy in 5, and as a natural result of ERT was instituted after a median interval of 84 months menopause in 24 (information was unavailable for the other following the diagnosis of breast cancer (range, 0 to 286 5 patients). During the observation period, the patients had months; mean { SEM, 94 { 10 months). Median duration regular evaluations with history and physical examination of ERT was 31 months (range, 24 to 142; mean { SEM, 47 every 3 to 6 months and annual mammograms, cervical cy-{ 10 months). Median period of follow-up was 144 months tologies, and electrocardiograms.
after diagnosis (range, 46 to 324 months). Three postmenoAll patients had surgery for treatment of breast cancer. pausal women were receiving ERT at the time of cancer Twelve women had surgery alone; 20 had surgery plus radio-diagnosis and continued to receive estrogen throughout the therapy; 10 had surgery plus chemotherapy; and 7 had sur-duration of their treatment. At their last evaluations these gery, radiotherapy, and chemotherapy.
patients still had no evidence of disease at 24, 96, and 106 months, respectively.
RESULTS
One patient with coexisting infertility, thyroid cancer, and type I diabetes mellitus experienced breast cancer recurPatients on Oral ERT rence. At the age of 42 years, this patient presented with a 1.5-cm left breast mass; excision biopsy showed infiltrating Forty-three women received oral ERT (Table 1) . Their lobular carcinoma and she underwent a modified radical median age at the time of cancer diagnosis was 46 years mastectomy. At surgery, 31 axillary lymph nodes were nega-(range, 26 to 66 years; mean { SEM, 47 { 1.5 years). The disease was classified as stage I in 22 women, stage II in 19, tive and ER was 16.8 fm/mg. A simple right mastectomy and latissimus dorsi dorsal myocutaneous flap reconstruc-months; mean { SEM, 46 { 6.0). The median duration of ERT was 47 months (range, 27 to 80 months; mean / SEM, tions were performed during the following months. ERT was prescribed 30 months later. A 1-cm mass was found in the 47 { 8.1 months). Median period of follow-up was 95 months after diagnosis (range, 72 to 154 months). There left breast, just above the flap reconstruction 56 months after initiation of ERT; wide local excision was performed and have been no cancer recurrences in this patient group. recurrent lobular carcinoma was found. Postoperatively she DISCUSSION was treated with six cycles of chemotherapy (5-FU, Adriamycin, and cyclophosphamide) and radiotherapy (50 Gy), With successful screening programs, detection of breast followed by Tamoxifen (10 mg twice daily) for 2 years. She cancer at an early stage (including lesions in situ) is becomwas disease-free at the time of last evaluation, 34 months ing more prevalent. Accordingly, we anticipate that treatafter the diagnosis of recurrence, 10 years after the initial ment of limited disease will result in higher rates of diseasediagnosis of breast cancer. free and overall survival. As a result, an ever-increasing number of prior breast cancer patients will join the growing Patients on Vaginal ERT population of aging women. However, women with a history of breast cancer are exposed to estrogen deficiency more Six women received ERT as a vaginal cream application (Table 1) . Their median age at the time of cancer diagnosis often and for longer periods of time than women in the general population. Natural menopause is frequently accelerwas 46 years (range, 38 to 57 years; mean { SEM, 46 { 2.7 years). Their disease was classified as stage I in 3 women, ated by chemotherapy [20, 21] which is increasingly being incorporated in treatment protocols for localized disease. stage II in 2, and stage III in 1. ER status was negative in 2 women, positive in 2, and unavailable in 2. Node status Furthermore, women with prior surgical menopause are urged to discontinue ERT at the time of breast cancer diagnowas negative in 3 women and positive in the other 3.
ERT was instituted after a median interval of 49 months sis. This practice stems from deep-seated concerns that ERT may precipitate cancer recurrence. following the diagnosis of breast cancer (range, 24 to 61 An outline of available studies is provided in Table 2 . ERT (with or without progesterone) has been described in 13. Cobleigh MA, Berris RF, Bush T, Davidson NE, Robert NJ, Sparano five recent studies [16] [17] [18] [19] including the present report. In
